文献速递临床试验与 GCP流行病学与生物统计

同时接种口服脊髓灰质炎疫苗降低轮状病毒疫苗IgA血清阳转率:33国II/III期试验汇总分析

Antirotavirus IgA seroconversion rates in children who receive concomitant oral poliovirus vaccine: A secondary, pooled analysis of Phase II and III trial data from 33 countries.
PubMed 文献 · PLoS Med · 2019-12-30

该研究汇总葛兰素史克RV1轮状病毒疫苗II/III期临床试验的个体数据,纳入33个国家/地区7,280名5-17周龄婴儿,分析同时接种OPV对抗轮状病毒IgA血清阳转和抗体滴度的影响。结果显示高儿童死亡率地区婴儿血清阳转 odds 较低(OR=0.48),首剂和第二剂RV1均同时接种OPV者血清阳转 odds 为0.63(95%CI 0.47-0.84,p=0.002),提示OPV干扰RV1免疫原性。

要点

  • 首剂和第二剂RV1均同时接种OPV者抗轮状病毒IgA血清阳转率显著降低(OR=0.63)。
  • 高儿童死亡率地区婴儿血清阳转 odds 低于低儿童死亡率地区(OR=0.48)。
  • 全球退出婴儿免疫规划中的OPV可能改善RV1疫苗性能。

核心结论

  • 与RV1同时接种OPV是抗轮状病毒IgA血清阳转率降低的重要贡献因素,该干扰在第二剂RV1后仍明显。
  • 全球退出婴儿免疫规划中的OPV有可能改善RV1疫苗性能。

研究设计与样本

  • 对葛兰素史克单价轮状病毒疫苗RV1(Rotarix)II期和III期临床试验的个体水平数据进行汇总分析。
  • 纳入22项试验、33个国家/地区共7,280名接种婴儿,首剂接种年龄5-17周。
  • 采用混合效应 logistic 回归和混合效应线性回归分析血清阳转和抗体滴度。

主要发现

  • 高儿童死亡率地区婴儿血清阳转 odds 低于低儿童死亡率地区(OR=0.48,95%CI 0.43-0.53,p<0.001)。
  • 高儿童死亡率地区血清阳转者抗轮状病毒IgA滴度低于低儿童死亡率地区(β=0.83,95%CI 0.77-0.90,p<0.001)。
  • 首剂和第二剂RV1均同时接种OPV者血清阳转 odds 为0.63(95%CI 0.47-0.84,p=0.002)。
  • 血清阳转者中,首剂和第二剂RV1均同时接种OPV与抗轮状病毒IgA滴度正相关(β=1.28,95%CI 1.07-1.53,p=0.009)。

关键数值与推荐

  • 抗轮状病毒IgA血清阳转定义为初始血清阴性者出现血清抗轮状病毒IgA抗体。
  • 血清学指标于末剂轮状病毒疫苗后约4-12周采集。

临床怎么用

  • 临床决策中应关注OPV与RV1同时接种对轮状病毒疫苗免疫应答的潜在干扰。
  • 在OPV仍用于婴儿免疫规划的地区,可考虑优化RV1与OPV的接种时序以提升免疫原性。

局限性

  • 分析仅限于临床试验环境中接种RV1的健康婴儿,结果外推至常规使用可能受限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite the success of rotavirus vaccines over the last decade, rotavirus remains a leading cause of severe diarrheal disease among young children. Further progress in reducing the burden of disease is inhibited, in part, by vaccine underperformance in certain settings. Early trials suggested that oral poliovirus vaccine (OPV), when administered concomitantly with rotavirus vaccine, reduces rotavirus seroconversion rates after the first rotavirus dose with modest or nonsignificant interference after completion of the full rotavirus vaccine course. Our study aimed to identify a range of individual-level characteristics, including concomitant receipt of OPV, that affect rotavirus vaccine immunogenicity in high- and low-child-mortality settings, controlling for individual- and country-level factors. Our central hypothesis was that OPV administered concomitantly with rotavirus vaccine reduced rotavirus vaccine immunogenicity. METHODS AND FINDINGS: Pooled, individual-level data from GlaxoSmithKline's Phase II and III clinical trials of the monovalent rotavirus vaccine (RV1), Rotarix, were analyzed, including 7,280 vaccinated infants (5-17 weeks of age at first vaccine dose) from 22 trials and 33 countries/territories (5 countries/territories with high, 13 with moderately low, and 15 with very low child mortality). Two standard markers for immune response were examined including antirotavirus immunoglobulin A (IgA) seroconversion (defined as the appearance of serum antirotavirus IgA antibodies in subjects initially seronegative) and serum antirotavirus IgA titer, both collected approximately 4-12 weeks after administration of the last rotavirus vaccine dose. Mixed-effect logistic regression and mixed-effect linear regression of log-transformed data were used to identify individual- and country-level predictors of seroconversion (dichotomous) and antibody titer (continuous), respectively. Infants in high-child-mortality settings had lower odds of seroconverting compared with infants in low-child-mortality settings (odds ratio [OR] = 0.48, 95% confidence interval [CI] 0.43-0.53, p < 0.001). Similarly, among those who seroconverted, infants in high-child-mortality settings had lower IgA titers compared with infants in low-child-mortality settings (mean difference [β] = 0.83, 95% CI 0.77-0.90, p < 0.001). Infants who received OPV concomitantly with both their first and their second doses of rotavirus vaccine had 0.63 times the odds of seroconverting (OR = 0.63, 95% CI 0.47-0.84, p = 0.002) compared with infants who received OPV but not concomitantly with either dose. In contrast, among infants who seroconverted, OPV concomitantly administered with both the first and second rotavirus vaccine doses was found to be positively associated with antirotavirus IgA titer (β = 1.28, 95% CI 1.07-1.53, p = 0.009). Our findings may have some limitations in terms of generalizability to routine use of rotavirus vaccine because the analysis was limited to healthy infants receiving RV1 in clinical trial settings. CONCLUSIONS: Our findings suggest that OPV given concomitantly with RV1 was a substantial contributor to reduced antirotavirus IgA seroconversion, and this interference was apparent after the second vaccine dose of RV1, as with the original clinical trials that our reanalysis is based on. However, our findings do suggest that the forthcoming withdrawal of OPV from the infant immunization schedule globally has the potential to improve RV1 performance.

来源:PLoS Med,查看原文。版权归原作者所有。

引用

  1. Baker JM, Tate JE, Leon J, et al. Antirotavirus IgA seroconversion rates in children who receive concomitant oral poliovirus vaccine: A secondary, pooled analysis of Phase II and III trial data from 33 countries. PLoS Med. 2019. PMID: 31887139. doi:10.1371/journal.pmed.1003005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。